Robert B. Naso
Nessuna posizione attualmente
Profilo
Robert B.
Naso has been an Executive Vice President of Research and Development for Affymax, Inc. since 2004.
From 1995 to 2004, he was Senior Vice President of Research and Development for Nabi Biopharmaceuticals and Vice President of Research and Vice President of Research and Development for Univax Biologics, Inc. from 1992 to 1995.
From 1983 to 1992, Dr. Naso held various positions at Johnson & Johnson, including Director of Bioscience at the R.W.
Johnson Pharmaceutical Research Institute.
He was a Faculty Member of The University of Texas and Managing Director of the Anderson Hospital and Tumor Institute from 1973 to 1983.
Dr. Naso received a PhD from West Virginia University and a BA degree from the State University of New York.
Precedenti posizioni note di Robert B. Naso
| Società | Posizione | Fine |
|---|---|---|
| AFFYMAX, INC. | Direttore Tecnico/Scientifico/R&S | 31/12/2007 |
Univax Biologics, Inc.
 Univax Biologics, Inc. BiotechnologyHealth Technology Univax Biologics, Inc. developed and manufactured anti-infective products. The firm developed different products that prevented and treated infectious diseases and related complications through activation targeting of human immune system. Its products included vaccines for long-term protection, specific polyclonal antibodies for short-term protection and therapeutic intervention. The company was founded in 1988 and was located in Rockville, MD. | Direttore Tecnico/Scientifico/R&S | 01/01/1995 |
| R.W. Johnson Pharmaceutical Research Institute | Corporate Officer/Principal | 01/01/1992 |
Nabi Biopharmaceuticals
 Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Robert B. Naso
| State University of New York at Buffalo | Undergraduate Degree |
| West Virginia University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| AFFYMAX, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Health Technology |
Univax Biologics, Inc.
Univax Biologics, Inc. BiotechnologyHealth Technology Univax Biologics, Inc. developed and manufactured anti-infective products. The firm developed different products that prevented and treated infectious diseases and related complications through activation targeting of human immune system. Its products included vaccines for long-term protection, specific polyclonal antibodies for short-term protection and therapeutic intervention. The company was founded in 1988 and was located in Rockville, MD. | Health Technology |
| R.W. Johnson Pharmaceutical Research Institute |
- Borsa valori
- Insiders
- Robert B. Naso
